M. Birgitte Visch

M. Birgitte Visch

Auto-generated profile, based on publicly available information

M. Birgitte Visch

Department of Dermatology, Ziekenhuis Rijnstate, Arnhem, the Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
WWW. Woliner–Van der Weg
W. Woliner–Van der Weg
MPM. Peppelman
M. Peppelman
YEY.S. Elshot
Y.S. Elshot
MVM.B. Visch
M.B. Visch
MCM.B. Crijns
M.B. Crijns
SLS.F.K. Lubeek
S.F.K. Lubeek
Background Reflectance confocal microscopy (RCM) is a non‐invasive method for skin assessment, allowing entire lesion evaluation up to the papillary dermis. Therefore, RCM is a potentially attractive alternative to punch biopsy in basal cell carcinoma (BCC). Objectives and design This randomized controlled trial aimed to investigate RCM as alternative to punch biopsy in a real‐world clinical setting. Primary objective was to determine the diagnostic accuracy of RCM compared to punch biopsy in diagnosing and subtyping BCC. Secondary objectives were to study related patient satisfaction and preferences. Methods Patients with a clinically suspected primary BCC were randomized between RCM and biopsy. Conventional surgical excision or follow‐up were used as reference. Sensitivity and specificity for BCC diagnosis and subtyping were calculated for both methods. BCC subtype was stratified based on clinical relevance: aggressive (infiltrative/micronodular) versus non‐aggressive (superficial/nodular) histopathological subtype and superficial versus non‐superficial BCC. Data on patient satisfaction and preferences werecollected using a questionnaire and a contingent valuation method. Results Sensitivity for BCC diagnosis was high and similar for both methods (RCM 99.0% versus biopsy 99.0%, p=1.00). Specificity for BCC diagnosis was lower with RCM (59.1% versus 100.0%, p<0.001). Sensitivity for aggressive BCC subtypeswas lower for RCM (33.3% versus 77.3%, p=0.003). Sensitivity for non‐superficial BCC was not significantly different (RCM 88.9% versus biopsy 91.0%, p=0.724). Patient satisfaction and preferences were good and highly comparable for both methods. Conclusions Biopsy outperforms RCM in diagnosing and subtyping clinically suspected primary BCC. This outcome does not support routine clinical implementation of RCM, as a replacement of punch biopsies in this patient group.

21 July 2022 in Drugs & Aging
Verified
Journal Article
Open access
PDF file
EHElke ter Haar
Elke ter Haar
STS. E. Thomas
S. E. Thomas
JRJ. M. P. A. van Den Reek
J. M. P. A. van Den Reek
MOM. E. Otero
M. E. Otero
MNM. D. Njoo
M. D. Njoo
EJE. M. G. J. de Jong
E. M. G. J. de Jong
Background Psoriasis is a common inflammatory disease in any age group, but also in older patients (≥ 65 years of age). Since older patients are often excluded from clinical trials, limited data specifically on this growing population are available, e.g. regarding the safety and performance of biological treatment. Aims We aimed to give insight into this specific population by comparing the drug survival and safety of biologics in older patients with that in younger patients. Methods In this real-world observational study, data from 3 academic and 15 non-academic centers in The Netherlands were extracted from the prospective BioCAPTURE registry. Biologics included in this study were tumor necrosis factor (TNF)-α, interleukin (IL)-17, IL-12/23, and IL-23 inhibitors. Patients were divided into two age groups: ≥ 65 years and < 65 years. The Charlson Comorbidity Index (CCI) was used to measure comorbid disease status, and all adverse events (AEs) that led to treatment discontinuation were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) classification. All AEs that led to treatment discontinuation were studied to check whether they could be classified as serious AEs (SAEs). Kaplan–Meier survival curves for overall 5-year drug survival and split according to reasons of discontinuation (ineffectiveness or AEs) were constructed. Cox regression models were used to correct for possible confounders and to investigate associations with drug survival in both age groups separately. Psoriasis Area and Severity Index (PASI) scores during the first 2 years of treatment and at the time of treatment discontinuation were assessed and compared between age groups. Results A total of 890 patients were included, of whom 102 (11.4%) were aged ≥ 65 years. Body mass index, sex, and distribution of biologic classes (e.g. TNFα, IL12/23) were not significantly different between the two age groups. A significantly higher CCI score was found in older patients, indicative of more comorbidity (p < 0.001). The 5-year ineffectiveness-related drug survival was lower for older patients (44.5% vs. 60.5%; p = 0.006), and the 5-year overall (≥ 65 years: 32.4% vs. < 65 years: 42.1%; p = 0.144) and AE-related (≥ 65 years: 82.1% vs. < 65 years: 79.5%; p = 0.913) drug survival was comparable between age groups. Of all AEs (n = 155) that led to discontinuation, 16 (10.3%) were reported as SAEs but these only occurred in younger patients. After correcting for confounders, the same trends were observed in the drug survival outcomes. Linear regression analyses on PASI scores showed no statistical differences at 6, 12, 18, and 24 months of treatment between age groups. Conclusions This study in a substantial, well-defined, prospective cohort provides further support that the use of biologics in older patients seems well-tolerated and effective. Biologic discontinuation due to AEs did not occur more frequently in older patients. Older patients discontinued biologic treatment more often due to ineffectiveness, although no clear difference in PASI scores was observed. More real-world studies on physician- and patient-related factors in older patients are warranted.

24 June 2022 in JEADV Clinical Practice
Verified
Journal Article
Open access
LSLara S. van der Schoot
Lara S. van der Schoot
HGHans Groenewoud
Hans Groenewoud
MGMarleen van Gelder
Marleen van Gelder
MOMarisol E. Otero
Marisol E. Otero
WAW. Peter Arnold
W. Peter Arnold
JRJuul M. P. A. van Den Reek
Juul M. P. A. van Den Reek
Background: Limited real‐world studies are available comparing infection risk between biologics for psoriasis.Objectives: The primary aim was to determine the differential effect of currently available biologics on the risk of respiratory tract infections (RTI) among psoriasis patients in a real‐world setting. Secondary aims were to explore the differential risk of all types of serious infections (SI) between biologics and to provide an early overview of SARS‐CoV‐2 infections during the pre‐vaccine era.Methods: Crude incidence rates of RTI and SI were calculated per 100 patient‐years (PY) per biologic using prospective BioCAPTURE data. Negative Binomial Regression modeling was used to explore the risk of RTI. Frailty Cox proportional hazards modeling was used to estimate hazard ratios for the risk of the first SI. Confounders adjusted for both models were selected by a directed acyclic graph. A post hoc exploratory analysis of SARS‐CoV‐2 infection incidence rates during 2020 was performed.Results: We included 714 patients with 1325 treatment episodes (3607.7PY between 2005 and 2020), in which 2224 RTI and 63 SI occurred. Among RTI, 1.3% were serious. The crude incidence rates were 61.7 (95% confidence interval [CI]: 59.1–64.3) per 100PY for RTI, and 1.8 (95% CI: 1.4–2.2) per 100PY for SI. Confounder adjusted analyses showed no differential risk of RTI between adalimumab, etanercept, infliximab, ustekinumab, secukinumab, ixekizumab and guselkumab. For SI, no differential risk was found between biologics either. Extended single‐center data showed 3.8 (95% CI: 2.2–6.1) SARS‐CoV‐2 infections per 100PY in 2020.Conclusions: Confounder adjusted analyses showed no differential risks of RTI or SI between included biologics (adalimumab, etanercept, infliximab, ustekinumab, secukinumab, ixekizumab and guselkumab) in a prospective psoriasis patients cohort. In general, absolute numbers of all types of SI were low.